secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pluri Inc. (PLUR)
CIK:        0001158780
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001213900-23-056039
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Pluri signs $4.2M NIAID contract to develop PLX-R18 cell therapy for H-ARS
--------------------------------------------------------------------------

- Three-year, $4.2M contract with NIAID to advance PLX-R18 for Hematopoietic Acute Radiation Syndrome (H-ARS).
- Company will collaborate with U.S. DOD's AFRRI and Uniformed Services University of Health Sciences (USUHS).
- Program funded by NIAID, part of the National Institutes of Health (NIH).
- PLX-R18 is a potential novel treatment for radiation exposure from nuclear disasters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1158780/000121390023056039/0001213900-23-056039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1158780/000121390023056039/ea181617-8k_pluriinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-056039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer